Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in the Li-Fraumeni Syndrome model, Trp53+/- mice

Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in the Li-Fraumeni Syndrome model, Trp53+/- mice

Bibliographic Details
Main Authors:	Blackburn, Anneke C, Rooke, Melissa, Li, Yiming, Dahlstrom, Jane E, Board, Philip G
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073007/

Similar Items

Chemoprevention with the metabolism modifying drugs dichloroacetate and metformin in Trp53+/- mice
by: Blackburn, AC, et al.
Published: (2012)

Dichloroacetate is an effective treatment for sarcoma models in vitro and in vivo
by: Rooke, Melissa, et al.
Published: (2014)

Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells
by: Sun, Ramon C, et al.
Published: (2011)

Constitutional p53 mutation in a non-Li-Fraumeni cancer family.
by: Prosser, J., et al.
Published: (1992)

Hormonal control of p53 and chemoprevention
by: Jerry, D Joseph, et al.
Published: (2002)

Li-Fraumeni syndrome--a molecular and clinical review.
by: Varley, J. M., et al.
Published: (1997)

The first documentation of Li-Fraumeni syndrome in Korea.
by: Bang, Y. J., et al.
Published: (1995)

Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.
by: Birch, J. M., et al.
Published: (1994)

Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
by: Blackburn, Anneke C, et al.
Published: (2002)

A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53
by: Glazer, Robert I.
Published: (2010)

Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations
by: Xu, Jie, et al.
Published: (2014)

The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations
by: Silva, Amanda G, et al.
Published: (2014)

A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families
by: Calvete, Oriol, et al.
Published: (2015)

TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome
by: Ribi, Sebastian, et al.
Published: (2015)

Caspase Activation and Aberrant Cell Growth in a p53+/+ Cell Line from a Li-Fraumeni Syndrome Family
by: Sherif, Zaki A.
Published: (2015)

Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome
by: Park, Kyoung-Jin, et al.
Published: (2016)

Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families.
by: Boyle, J. M., et al.
Published: (1998)

Li-Fraumeni syndrome: a case report from Italy.
by: Orjuela, M., et al.
Published: (1990)

Li Fraumeni syndrome, cancer and senescence: a new hypothesis
by: Pantziarka, Pan
Published: (2013)

Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche
by: Pantziarka, Pan
Published: (2015)

Does PTEN gene mutation play any role in Li-Fraumeni syndrome
by: Akouchekian, Mansoureh, et al.
Published: (2016)

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy
by: Spees, Colleen K., et al.
Published: (2015)

The Benefit and Burden of Cancer Screening in Li-Fraumeni Syndrome: A Case Report
by: Jhaveri, Ami P., et al.
Published: (2015)

Genetic and functional analysis of a Li Fraumeni syndrome family in China
by: Hu, Huaying, et al.
Published: (2016)

PEComa in a Young Patient with Known Li-Fraumeni Syndrome
by: Neofytou, Kyriakos, et al.
Published: (2015)

Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.
by: Sedlacek, Z., et al.
Published: (1998)

The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/–) and Trp53(−/−) mice
by: Krais, Annette M., et al.
Published: (2015)

Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy
by: Khan, Akbar, et al.
Published: (2016)

p53 Regulation by TRP2 Is Not Pervasive in Melanoma
by: Houben, Roland, et al.
Published: (2014)

A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: a patient with Wilms' tumour is not a mutation carrier.
by: Varley, J. M., et al.
Published: (1998)

Clinical pharmacology and toxicology of dichloroacetate.
by: Stacpoole, P W, et al.
Published: (1998)

Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?
by: McAllister, Kimberly A, et al.
Published: (2002)

Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity
by: van der Weyden, L, et al.
Published: (2013)

No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.
by: Williams, K. J., et al.
Published: (1996)

A Case of Late-Onset Li-Fraumeni-like Syndrome with Unilateral Breast Cancer
by: Cho, Yonggeun, et al.
Published: (2013)

Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion
by: Silva, Amanda Gonçalves, et al.
Published: (2012)

Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy
by: Yoshida, Go J, et al.
Published: (2012)

Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature
by: Kast, Karin, et al.
Published: (2012)

Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity
by: Judith Penkert, et al.
Published: (2018-08-01)

Síndrome de Li-Fraumeni: uma abordagem para identificação e aconselhamento genético de portadores
by: Débora Aparecida Rodrigueiro, et al.
Published: (2016-10-01)